Commonly asked questions in the treatment of obsessive-compulsive disorder

被引:11
作者
Arumugham, Shyam Sundar [1 ]
Reddy, Y. C. Janardhan [1 ]
机构
[1] Natl Inst Mental Hlth & NeuroSci NIMHANS, Dept Psychiat, Obsess Compuls Disorder OCD Clin, Bangalore 560029, Karnataka, India
关键词
augmentation; behavior therapy; cognitive-behavior therapy; obsessive-compulsive disorder; psychosurgery; repetitive transcranial magnetic stimulation; selective serotonin reuptake inhibitor; treatment; COGNITIVE-BEHAVIORAL THERAPY; TRANSCRANIAL MAGNETIC STIMULATION; SEROTONIN REUPTAKE INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; D-CYCLOSERINE; SCHIZOPHRENIA-PATIENTS; RESPONSE PREVENTION; CLINICAL-TRIAL;
D O I
10.1586/14737175.2014.874287
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Obsessive-compulsive disorder (OCD) is a common and often a highly disabling condition that was considered untreatable before the 1960s. The advent of serotonin reuptake inhibitors and exposure and response prevention revolutionized the treatment of OCD. Although they are still the first line treatments for OCD, new treatments like augmentation strategies, brain stimulation techniques, psychosurgery, newer forms of psychotherapy (like cognitive therapy, acceptance and commitment therapy) have been added to the armamentarium. With the available treatment strategies, many patients can achieve at least partial remission of symptoms. Nevertheless, the plethora of information gives rise to many questions on their application for practicing clinicians. We provide evidence-based responses to these questions and suggest a broad guideline for treatment of OCD.
引用
收藏
页码:151 / 163
页数:13
相关论文
共 142 条
[1]  
Abramowitz Jonathan S., 2005, Cognitive Behaviour Therapy, V34, P140, DOI 10.1080/16506070510041202
[2]   Variants of exposure and response prevention in the treatment of obsessive-compulsive disorder: A meta-analysis [J].
Abramowitz, JS .
BEHAVIOR THERAPY, 1996, 27 (04) :583-600
[3]   N-Acetylcysteine Add-On Treatment in Refractory Obsessive-Compulsive Disorder A Randomized, Double-Blind, Placebo-Controlled Trial [J].
Afshar, Hamid ;
Roohafza, Hamidreza ;
Mohammad-Beigi, Hamid ;
Haghighi, Mohammad ;
Jahangard, Leila ;
Shokouh, Pedram ;
Sadeghi, Masoumeh ;
Hafezian, Hasan .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (06) :797-803
[4]   A randomized controlled clinical trial of Citalopram versus Fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD) [J].
Alaghband-Rad, Javad ;
Hakimshooshtary, Mitra .
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2009, 18 (03) :131-135
[5]   Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: A preliminary single-blind, 12-week, controlled study [J].
Albert, U ;
Aguglia, E ;
Maina, G ;
Bogetto, F .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (11) :1004-1009
[6]   Effectiveness of Cognitive-Behavioral Therapy Addition to Pharmacotherapy in Resistant Obsessive-Compulsive Disorder: A Multicenter Study [J].
Albert, Umberto ;
Aguglia, Andrea ;
Bogetto, Filippo ;
Cieri, Luca ;
Daniele, Marinella ;
Maina, Giuseppe ;
Necci, Roberta ;
Parena, Anita ;
Salvati, Loretta ;
Tundo, Antonio .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 2012, 81 (06) :383-385
[7]  
Albert U, 2012, RIV PSICHIATR, V47, P255, DOI 10.1708/1139.12553
[8]   Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: A prospective 1-year follow-up study [J].
Anand, Nitin ;
Sudhir, Paulomi M. ;
Math, Suresh Bada ;
Thennarasu, K. ;
Reddy, Y. C. Janardhan .
JOURNAL OF ANXIETY DISORDERS, 2011, 25 (07) :939-945
[9]  
Arumugham SS, 2013, EXPERT REV NEUROTHER, V13, P187, DOI [10.1586/ERN.12.160, 10.1586/ern.12.160]
[10]   Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder A Randomized, Double-Blind, Placebo-Controlled Trial [J].
Askari, Neda ;
Moin, Mandieh ;
Sanati, Mohammad ;
Tajdini, Masih ;
Hosseini, Seyed-Mohammad-Reza ;
Modabbernia, Amirhossein ;
Najand, Babak ;
Salimi, Samrand ;
Tabrizi, Mina ;
Ashrafi, Mandana ;
Hajiaghaee, Reza ;
Akhondzadehl, Shahin .
CNS DRUGS, 2012, 26 (10) :883-892